MetLife Investment Management’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.12M | Sell |
62,717
-1,509
| -2% | -$26.9K | 0.01% | 1247 |
|
|
2025
Q1 | $1.14M | Sell |
64,226
-1,093
| -2% | -$19.5K | 0.01% | 1292 |
|
|
2024
Q4 | $1.95M | Buy |
65,319
+3,716
| +6% | +$111K | 0.01% | 1059 |
|
|
2024
Q3 | $963K | Buy |
61,603
+34,711
| +129% | +$543K | 0.01% | 1407 |
|
|
2024
Q2 | $461K | Buy |
26,892
+20,511
| +321% | +$351K | ﹤0.01% | 1763 |
|
|
2024
Q1 | $99.7K | Buy |
6,381
+20
| +0.3% | +$313 | ﹤0.01% | 2540 |
|
|
2023
Q4 | $95K | Buy |
+6,361
| New | +$95K | ﹤0.01% | 2632 |
|
|
2023
Q3 | – | Sell |
-6,445
| Closed | -$267K | – | 2953 |
|
|
2023
Q2 | $267K | Buy |
6,445
+185
| +3% | +$7.68K | ﹤0.01% | 2089 |
|
|
2023
Q1 | $376K | Buy |
6,260
+15
| +0.2% | +$902 | ﹤0.01% | 1820 |
|
|
2022
Q4 | $458K | Sell |
6,245
-165
| -3% | -$12.1K | ﹤0.01% | 1696 |
|
|
2022
Q3 | $487K | Buy |
6,410
+5
| +0.1% | +$380 | ﹤0.01% | 1653 |
|
|
2022
Q2 | $445K | Sell |
6,405
-218
| -3% | -$15.2K | ﹤0.01% | 1744 |
|
|
2022
Q1 | $549K | Buy |
+6,623
| New | +$549K | ﹤0.01% | 1718 |
|
|
2020
Q2 | – | Sell |
-36,576
| Closed | -$2.46M | – | 2336 |
|
|
2020
Q1 | $2.46M | Sell |
36,576
-1,147
| -3% | -$77.2K | 0.03% | 525 |
|
|
2019
Q4 | $3.18M | Hold |
37,723
| – | – | 0.03% | 600 |
|
|
2019
Q3 | $2.82M | Buy |
37,723
+4,562
| +14% | +$341K | 0.03% | 635 |
|
|
2019
Q2 | $2.1M | Hold |
33,161
| – | – | 0.02% | 794 |
|
|
2019
Q1 | $1.6M | Buy |
+33,161
| New | +$1.6M | 0.02% | 902 |
|